Guten Tag allerseits! I want to share my experience getting Wegovy covered by my gesetzliche Krankenkasse (GKV) — specifically Techniker Krankenkasse (TK) — through their new Adipositas treatment programme.
Background: BMI 39, diagnosed Adipositas Grad II, with arterielle Hypertonie and Schlafapnoe. My Hausarzt (GP) referred me to an Adipositas-Zentrum at the LMU Klinikum München.
Here's the timeline:
- March 2025: Initial Hausarzt referral
- May 2025: First appointment at the Adipositas-Zentrum
- May-November 2025: Required 6-month "multimodales Basisprogramm" (diet counselling, exercise therapy, psychological evaluation)
- December 2025: Antrag (application) submitted to TK for Wegovy Kostenübernahme
- February 2026: APPROVED! TK agreed to cover Wegovy under their "besondere Versorgung" programme
Total time from first GP visit to approved Wegovy prescription: 11 months. Not quick, but it works.
This is incredibly helpful. I'm with AOK Niedersachsen and I've been trying to get Wegovy covered since mid-2025. My experience has been different — and worse.
AOK rejected my Antrag twice, citing that Wegovy is a "Lifestyle-Arzneimittel" and excluded under §34 SGB V (the section of German social law that excludes appetite suppressants from GKV coverage). They're treating it the same as old drugs like orlistat.
My Adipositas-Arzt (obesity specialist) filed a Widerspruch (formal objection) arguing that the G-BA (Gemeinsamer Bundesausschuss) ruling from September 2025 specifically states semaglutide 2.4mg is NOT classified as an Appetitzügler but as an Antiadipositum with metabolic effects. The Widerspruch is still pending after 8 weeks.
The German system is kafkaesque. One Krankenkasse approves it, the other rejects it for the same patient profile. It shouldn't depend on which insurance card you carry.
The §34 SGB V issue is THE central problem in Germany. Until the Bundestag amends the law to explicitly exclude modern GLP-1 agonists from the "Lifestyle" classification, individual Kassen will keep playing this game.
That said, there's been progress. The G-BA Beschluss (ruling) from 18. September 2025 did create a pathway. Key quote from the ruling:
"Semaglutid 2,4 mg (Wegovy) ist bei Patienten mit Adipositas Grad II oder höher (BMI ≥ 35 kg/m²) mit mindestens einer gewichtsbedingten Komorbidität verordnungsfähig, sofern ein strukturiertes multimodales Therapiekonzept vorliegt."
Translation: Wegovy IS prescribable for BMI 35+ with at least one weight-related comorbidity IF there's a structured multimodal therapy concept in place.
The problem is that this is a G-BA recommendation, not a binding directive. Each Krankenkasse decides independently whether to follow it.
Kassen known to cover Wegovy as of early 2026:
- Techniker Krankenkasse (TK) — yes, through besondere Versorgung
- BARMER — yes, case-by-case Einzelfallprüfung
- DAK-Gesundheit — yes, with Adipositas-Programm participation
- AOK Bayern — yes (but AOK Niedersachsen says no — go figure)
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsI went the Privatrezept (private prescription) route because my AOK Hessen also rejected coverage. Cost breakdown for Wegovy in Germany on private pay:
- 0.25mg starter: €141.18 (Apothekenverkaufspreis)
- 0.5mg: €141.18
- 1.0mg: €235.29
- 1.7mg: €235.29
- 2.4mg maintenance: €301.34/month
These are the official AVP prices — every Apotheke in Germany charges the same (Preisbindung). There is no shopping around on price.
At €301/month for the maintenance dose, it's not cheap but it's a fraction of US prices. I've been paying out of pocket since October 2025 and have lost 18kg. At some point the Kasse math will work out — treating my Adipositas-related conditions costs them far more than €301/month.
Dr.EndoEP — I'd strongly recommend escalating to the Sozialgericht (social court) if your Widerspruch is rejected. There have been several favorable rulings in 2025-2026 where courts ordered Kassen to cover Wegovy.
The key case is SG München, Urteil vom 14.11.2025, Az. S 7 KR 528/25 — the court ruled that TK was required to cover Wegovy for a patient with BMI 42 and T2D, finding that the §34 exclusion did NOT apply to semaglutide because its primary mechanism is metabolic, not appetite suppression.
Getting a Sozialgericht ruling takes 6-12 months, but it's free (no court costs in social court proceedings) and you can represent yourself without a lawyer.